Making a Difference

As a leader in the field of immunology, AbbVie is committed to supporting innovation that will continue to advance education and patient care for complex immunologic conditions.

We provide educational support in the following areas:

• Addressing the burden of disease;Understanding new discoveries and new therapies in development; and
• Supporting capacity-building initiatives aimed at increasing the number of healthcare providers across immunology specialties.

We will consider requests in the following areas: 

Rheumatology

• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondyloarthritis
• Uveitis

Dermatology

• Atopic Dermatitis
• Hidradenitis Suppurativa
• Nail Psoriasis
• Psoriasis
• Psoriatic Arthritis

Gastroenterology

• Crohn’s Disease – adult and pediatric
• Inflammatory Bowel Disease
• Ulcerative Colitis

Combining our deep knowledge of biology with innovative technologies, AbbVie is committed to supporting education of scientific advances for those living with and treating widespread and debilitating cancers.  

Oncology is a rapidly changing area. It is important to provide resources to help patients and healthcare providers navigate the evolving landscape of blood cancers and solid tumors.

We provide educational support in the following areas:

• Staying abreast of the rapidly evolving cancer landscape and science;
• Understanding the importance and relevance of biomarkers and cytogenetic testing;
• Developing and enhancing skills aimed at a meaningful co-management of disease; and
• Improving communication between patients and care team members

We will consider requests in the following areas:

Hematologic Malignancies

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Myelofibrosis
• Other Hematologic Malignancies

Solid Tumors

• Non-Small Cell Lung Cancer

Our goal is to provide education and support aimed at patients and  healthcare providers managing difficult-to-treat neurological diseases as well as urologic syndromes and dysfunction associated with these conditions.

We provide educational support in the following areas:

• Addressing the shortage of healthcare providers dedicated to the field of movement disorders; Understanding the staging of Parkinson’s Disease and corresponding appropriate therapies; 
• Educating patients and their care partners to be active and engaged participants in their care; and 
• New discoveries of neuroscience and new therapies in development.
  

We will consider requests in the following areas:

• Parkinson’s Disease
• Acute Treatment of Migraine
• Prevention of Episodic and Chronic Migraine Bipolar Depression
• Spasticity/Movement Disorders

With the increase in technological advances and the growing field of aesthetic medicine, we are committed to educating the healthcare community and their patients by supporting scientific, evidence-based initiatives.

We provide educational support in the following areas:

• Supporting education on non-surgical and non-invasive techniques to achieve the best patient outcomes; 
• Enhancing clinician understanding of how to communicate, treat and manage patients; and 
• Supporting educational initiatives with the goal of achieving optimal outcomes for patients in breast implant-based surgery and acellular dermal matrix-based surgery.
  

We will consider requests in the following areas:

• Non-Invasive Body Contouring 
• Non-Surgical Facial Aesthetics
• Plastics and Regenerative Medicine

We are committed to improving the quality of life for patients with a focus on disease areas where significant unmet need still exists. For example, Cystic Fibrosis and Exocrine Pancreatic Insufficiency/Pancreatitis. We also support innovation from early stages of bench science up to late stage clinical development to advance cutting-edge science outside of our own walls.

AbbVie is committed to advancing healthcare professionals knowledge of such infections to quickly diagnosis and manage patients for optimal outcomes.  

We will provide educational support in the following areas:

• The impact of early and appropriate antibiotic treatment strategies for high-risk patients across the continuum of care
• Increase awareness of appropriate antibiotic coverage & treatment
• Individualize and improve patient care for resistant bacterial infections

We will consider requests in the following areas:

• Community-Acquired and Healthcare-Associated Infections (i.e., bacterial skin and skin structure infections, urinary tract infections, intra-abdominal infections) caused by:
  • Gram-negative pathogens (i.e., carbapenem resistant enterobacterales and multi-drug resistant Pseudomonas Aeruginosa)
  • Gram-positive pathogens (i.e., methicillin resistant Staphylococcus- Aureus (MRSA), methicillin-susceptible Streptococcus aureus (MSSA) and penicillin resistant Streptococcus pneumoniae (PRSP)